Grigorios Rallis1, Triantafyllia Koletsa2, Zenia Saridaki3, Kyriaki Manousou4, Georgia-Angeliki Koliou4, Ioannis Kostopoulos2, Vassiliki Kotoula2,5, Thomas Makatsoris6, Helen P Kourea7, Georgia Raptou2, Sofia Chrisafi3, Epaminontas Samantas8, Kleo Papaparaskeva9, Elissavet Pazarli10, Pavlos Papakostas11, Georgia Kafiri12, Davide Mauri13, Alexandra Papoudou-Bai14, Christos Christodoulou15, Kalliopi Petraki16, Nikolaos Dombros17, Dimitrios Pectasides18, George Fountzilas19,17. 1. Department of Medical Oncology, School of Health Sciences, Faculty of Medicine, Papageorgiou Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece. 2. Department of Pathology, School of Health Sciences, Faculty of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece. 3. Asklepios Oncology Department, Heraklion, Greece. 4. Section of Biostatistics, Hellenic Cooperative Oncology Group, Data Office, Athens, Greece. 5. Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki, Greece. 6. Division of Oncology, Department of Medicine, University Hospital, University of Patras Medical School, Patras, Greece. 7. Department of Pathology, University Hospital of Patras, Patras, Greece. 8. Third Department of Medical Oncology, Agii Anargiri Cancer Hospital, Athens, Greece. 9. Department of Pathology, General Hospital Konstantopouleio Agia Olga, Athens, Greece. 10. Department of Pathology, School of Health Sciences, Faculty of Medicine Thessaloniki, Papageorgiou Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece. 11. Oncology Unit, Hippokration Hospital, Athens, Greece. 12. Department of Pathology, Hippokration Hospital, Athens, Greece. 13. Department of Medical Oncology, Ioannina University Hospital, Ioannina, Greece. 14. Department of Pathology, Ioannina University Hospital, Ioannina, Greece. 15. Second Department of Medical Oncology, Metropolitan Hospital, Piraeus, Greece. 16. Pathology Department, Metropolitan Hospital, Piraeus, Greece. 17. Aristotle University of Thessaloniki, Thessaloniki, Greece. 18. Oncology Section, Second Department of Internal Medicine, Hippokration Hospital, Athens, Greece. 19. Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki, Greece fountzil@auth.gr.
Abstract
BACKGROUND/AIM: Early-stage colorectal cancer (CRC) carries a wide range of survival probabilities. Novel biomarkers in this setting are eagerly awaited. Cancer stem cells (CSCs) are considered one of the reasons for treatment failure. This study sought to determine whether activation of pathways governing the function of CSC's could correlate with treatment outcomes. MATERIALS AND METHODS: Tumor specimens from 325 patients were analyzed with immunohistochemistry (IHC) for Hedgehog and Notch pathway activation and results were correlated with prognosis. RESULTS: Positive Notch3 protein expression was an unfavorable prognostic factor for disease-free survival (DFS) and overall survival (OS) (HR=2.43, p=0.024 and HR=2.56, p=0.028, respectively). Activation of the Shh pathway showed univariately longer DFS (HR=0.49, p=0.032). Possible crosstalk between the two pathways was indicated. No further associations between pathway activation and outcome were evident. CONCLUSION: Apart from Notch 3, activation of the pathways, as indicated by IHC expression of their components, did not result in differences in terms of DFS or OS. Copyright
BACKGROUND/AIM: Early-stage colorectal cancer (CRC) carries a wide range of survival probabilities. Novel biomarkers in this setting are eagerly awaited. Cancer stem cells (CSCs) are considered one of the reasons for treatment failure. This study sought to determine whether activation of pathways governing the function of CSC's could correlate with treatment outcomes. MATERIALS AND METHODS: Tumor specimens from 325 patients were analyzed with immunohistochemistry (IHC) for Hedgehog and Notch pathway activation and results were correlated with prognosis. RESULTS: Positive Notch3 protein expression was an unfavorable prognostic factor for disease-free survival (DFS) and overall survival (OS) (HR=2.43, p=0.024 and HR=2.56, p=0.028, respectively). Activation of the Shh pathway showed univariately longer DFS (HR=0.49, p=0.032). Possible crosstalk between the two pathways was indicated. No further associations between pathway activation and outcome were evident. CONCLUSION: Apart from Notch 3, activation of the pathways, as indicated by IHC expression of their components, did not result in differences in terms of DFS or OS. Copyright
Authors: Rong Ding; Guoyu Li; Yueyi Yao; Lijuan Zhang; Xuan Zhang; Jiayi Li; Tao Shen; Yi Gao; Tao Wu; Shuzhen Kong; Ming Huang; Yunfeng Li Journal: J Physiol Biochem Date: 2021-09-23 Impact factor: 4.158
Authors: Jilani Purusottapatnam Shaik; Ibrahim O Alanazi; Akbar Ali Khan Pathan; Narasimha Reddy Parine; Majid A Almadi; Nahla A Azzam; Abdulrahman M Aljebreen; Othman Alharbi; Mohammad Saud Alanazi; Zahid Khan Journal: J Oncol Date: 2020-03-09 Impact factor: 4.375